Hyperuricemia and gout among heart transplant recipients receiving cyclosporine

David A. Burack, Bartley P. Griffith, Mark E. Thompson, Leslie Kahl

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

purpose: To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients. patients and methods: One hundred ninetysix surviving adult heart or heart/lung transplant recipients were evaluated. Medical records were reviewed to determine peak serum uric acid levels after transplantation, and to evaluate potential risk factors for hyperuricemia. Patients were surveyed by postal questionnaire for a history of gouty arthritis, with positive responses evaluated by telephone interview and/or examination of the patient. results: Hyperuricemia occurred in 72% of male and 81% of female patients and was not correlated with cyclosporine level, presence of hypertension, or degree of renal insufficiency. Eleven (6%) patients had gout prior to transplantation; 14 (8%) had onset of definite gout and seven (4%) had probable gout a mean of 17 months after transplantation. Polyarticular arthritis and/or tophi developed in six (43%) of the posttransplant-onset definite gout group within a mean of 31 months. conclusion: Both hyperuricemia and gouty arthritis occur with increased frequency among cyclosporine-treated heart or heart/lung transplant recipients. The clinical course of gout in these patients is often accelerated, with management complicated by the patients' renal insufficiency and interaction with transplant-related medications.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalThe American journal of medicine
Volume92
Issue number2
DOIs
StatePublished - 1992
Externally publishedYes

Fingerprint

Hyperuricemia
Gout
Cyclosporine
Gouty Arthritis
Transplantation
Renal Insufficiency
Lung
Transplant Recipients
Uric Acid
Arthritis
Medical Records
Interviews
Hypertension
Transplants
Serum

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. / Burack, David A.; Griffith, Bartley P.; Thompson, Mark E.; Kahl, Leslie.

In: The American journal of medicine, Vol. 92, No. 2, 1992, p. 141-146.

Research output: Contribution to journalArticle

Burack, David A. ; Griffith, Bartley P. ; Thompson, Mark E. ; Kahl, Leslie. / Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. In: The American journal of medicine. 1992 ; Vol. 92, No. 2. pp. 141-146.
@article{9995b914bac94a94bda112b5306a348e,
title = "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine",
abstract = "purpose: To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients. patients and methods: One hundred ninetysix surviving adult heart or heart/lung transplant recipients were evaluated. Medical records were reviewed to determine peak serum uric acid levels after transplantation, and to evaluate potential risk factors for hyperuricemia. Patients were surveyed by postal questionnaire for a history of gouty arthritis, with positive responses evaluated by telephone interview and/or examination of the patient. results: Hyperuricemia occurred in 72{\%} of male and 81{\%} of female patients and was not correlated with cyclosporine level, presence of hypertension, or degree of renal insufficiency. Eleven (6{\%}) patients had gout prior to transplantation; 14 (8{\%}) had onset of definite gout and seven (4{\%}) had probable gout a mean of 17 months after transplantation. Polyarticular arthritis and/or tophi developed in six (43{\%}) of the posttransplant-onset definite gout group within a mean of 31 months. conclusion: Both hyperuricemia and gouty arthritis occur with increased frequency among cyclosporine-treated heart or heart/lung transplant recipients. The clinical course of gout in these patients is often accelerated, with management complicated by the patients' renal insufficiency and interaction with transplant-related medications.",
author = "Burack, {David A.} and Griffith, {Bartley P.} and Thompson, {Mark E.} and Leslie Kahl",
year = "1992",
doi = "10.1016/0002-9343(92)90104-J",
language = "English (US)",
volume = "92",
pages = "141--146",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Hyperuricemia and gout among heart transplant recipients receiving cyclosporine

AU - Burack, David A.

AU - Griffith, Bartley P.

AU - Thompson, Mark E.

AU - Kahl, Leslie

PY - 1992

Y1 - 1992

N2 - purpose: To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients. patients and methods: One hundred ninetysix surviving adult heart or heart/lung transplant recipients were evaluated. Medical records were reviewed to determine peak serum uric acid levels after transplantation, and to evaluate potential risk factors for hyperuricemia. Patients were surveyed by postal questionnaire for a history of gouty arthritis, with positive responses evaluated by telephone interview and/or examination of the patient. results: Hyperuricemia occurred in 72% of male and 81% of female patients and was not correlated with cyclosporine level, presence of hypertension, or degree of renal insufficiency. Eleven (6%) patients had gout prior to transplantation; 14 (8%) had onset of definite gout and seven (4%) had probable gout a mean of 17 months after transplantation. Polyarticular arthritis and/or tophi developed in six (43%) of the posttransplant-onset definite gout group within a mean of 31 months. conclusion: Both hyperuricemia and gouty arthritis occur with increased frequency among cyclosporine-treated heart or heart/lung transplant recipients. The clinical course of gout in these patients is often accelerated, with management complicated by the patients' renal insufficiency and interaction with transplant-related medications.

AB - purpose: To determine the frequency and characteristics of hyperuricemia and gouty arthritis among cyclosporine-treated heart transplant recipients. patients and methods: One hundred ninetysix surviving adult heart or heart/lung transplant recipients were evaluated. Medical records were reviewed to determine peak serum uric acid levels after transplantation, and to evaluate potential risk factors for hyperuricemia. Patients were surveyed by postal questionnaire for a history of gouty arthritis, with positive responses evaluated by telephone interview and/or examination of the patient. results: Hyperuricemia occurred in 72% of male and 81% of female patients and was not correlated with cyclosporine level, presence of hypertension, or degree of renal insufficiency. Eleven (6%) patients had gout prior to transplantation; 14 (8%) had onset of definite gout and seven (4%) had probable gout a mean of 17 months after transplantation. Polyarticular arthritis and/or tophi developed in six (43%) of the posttransplant-onset definite gout group within a mean of 31 months. conclusion: Both hyperuricemia and gouty arthritis occur with increased frequency among cyclosporine-treated heart or heart/lung transplant recipients. The clinical course of gout in these patients is often accelerated, with management complicated by the patients' renal insufficiency and interaction with transplant-related medications.

UR - http://www.scopus.com/inward/record.url?scp=0026517712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026517712&partnerID=8YFLogxK

U2 - 10.1016/0002-9343(92)90104-J

DO - 10.1016/0002-9343(92)90104-J

M3 - Article

C2 - 1543197

AN - SCOPUS:0026517712

VL - 92

SP - 141

EP - 146

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 2

ER -